AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2014
Aug 1, 2014
6965_dirs_2014-08-01_faded6d7-b877-4ee0-950d-cd0a54d7d4b9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2014-08-01
Reporting Person: Kidron Miriam (Director, Chief Technology Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-08-01 | Common Stock | M | 142814 | $0.012 | Acquired | 142814 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-08-01 | Warrant (right to buy) | $0.012 | M | 142814 | Disposed | 2014-08-06 | Common Stock (142814) | Direct |
Footnotes
F1: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
F2: The warrant was originally granted to the reporting person on August 14, 2007 and amended on August 8, 2012, resulting in the deemed cancellation of the "old" warrant and the grant of a replacement warrant.
F3: The warrant was granted in recognition of the reporting person's contributions to the issuer in connection with the initial development of its current business.